sever
calpain
inhibitor
develop
use
agent
import
human
pathogen
therefor
investig
effect
mdl
potent
calpain
inhibitor
growth
leishmania
amazonensi
h
treatment
inhibitor
exhibit
dosedepend
antileishmani
activ
lethal
dose
ld
inhibitor
promot
cellular
alter
parasit
becom
short
round
calpainlik
protein
migrat
kda
identifi
western
blot
addit
calpainlik
molecul
identifi
cell
surfac
flagel
result
add
new
vitro
insight
exploit
calpain
inhibitor
treat
parasit
infect
add
famili
peptidas
list
potenti
target
develop
potent
specif
inhibitor
trypanosomatid
leishmaniasi
group
infecti
diseas
caus
differ
speci
leishmania
affect
million
peopl
per
year
although
leishmania
hypoendem
endem
countri
popul
countri
produc
leishmaniaposit
skin
test
rural
endem
area
illustr
contact
parasit
much
widespread
previous
thought
frequenc
subclin
case
well
document
human
mammalian
reservoir
inde
brazil
incid
subclin
case
leishmaniasi
higher
incid
clinic
case
infect
human
immunodefici
viru
hiv
increas
risk
develop
leishmaniasi
addit
visceralis
leishmania
strain
leishmania
amazonensi
classic
restrict
cutan
leishmaniasi
often
observ
patient
leishmaniahiv
coinfect
clinic
report
indic
correspond
author
tel
larg
proport
case
becom
unrespons
chemotherapi
gener
lack
effect
inexpens
chemotherapeut
agent
treat
protozoan
diseas
occur
mainli
develop
world
undoubt
one
diseas
leishmaniasi
pentaval
antimoni
drug
antimoni
sodium
stiboglucon
meglumin
antimoni
still
firstlin
treatment
leishmaniasi
affect
area
amphotericin
b
pentamidin
use
altern
drug
agent
expens
activ
oral
requir
longterm
parenter
administr
produc
seriou
side
effect
eg
cardiac
renal
toxic
moreov
resist
compound
becom
sever
problem
view
present
clinic
scenario
desir
new
drug
develop
peptidas
microbi
pathogen
attract
attent
mani
laboratori
role
pathogenesi
analysi
proteolyt
enzym
pathogen
organ
might
lead
design
power
chemotherapeut
agent
pathogen
context
calpain
inhibitor
appear
interest
altern
calpain
calciumregul
cytosol
cystein
peptidas
exist
two
major
isoform
mcalpain
calpain
requir
millimolar
micromolar
concentr
ca
respect
activ
role
calpain
remain
poorli
understood
may
involv
crucial
cellular
function
rearrang
cytoskelet
protein
protein
cleavag
activ
variou
receptor
proenzym
calpain
activ
human
appear
increas
normal
age
muscular
dystrophi
cataract
arthriti
alzheim
diseas
well
acut
trauma
includ
traumat
brain
injuri
spinal
cord
injuri
cerebr
cardiac
ischaemia
varieti
calpain
inhibitor
develop
potenti
clinic
util
inhibitor
shown
treat
alzheim
diseas
minimis
neuron
death
ischaemia
addit
inhibitor
promis
altern
treat
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
adenoviru
may
effect
inhibit
activ
hiv
latent
infect
cell
therefor
compound
analogu
deserv
evalu
potenti
therapi
treat
leishmaniasi
could
use
lead
compound
discoveri
potent
leishmania
inhibitor
context
investig
inhibitori
capabl
potent
calpain
inhibitor
mdl
l
amazonensi
aim
show
effect
growth
morpholog
parasit
addit
demonstr
presenc
calpain
homologu
l
amazonensi
western
blot
flow
cytometri
fluoresc
microscopi
analys
calpain
inhibitor
mdl
carbobenzoxyvalylphenylalani
zvalphecho
purchas
calbiochem
san
diego
ca
reagent
use
electrophoresi
buffer
compon
nitrocellulos
membran
reagent
chemiluminesc
detect
ecl
system
obtain
amersham
life
scienc
littl
chalfont
uk
dimethyl
sulfoxid
dmso
giemsa
acquir
merck
darmstadt
germani
schneider
medium
obtain
usbiolog
swampscott
foetal
bovin
serum
fb
low
molecular
mass
standard
rpmi
medium
purchas
gibco
brl
gaithersburg
md
thioglycol
trypan
blue
secondari
antibodi
purchas
sigma
chemic
co
st
loui
mo
reagent
analyt
grade
promastigot
form
l
amazonensi
josefa
strain
grown
schneider
medium
supplement
heatinactiv
fb
c
day
reach
latelog
phase
growth
effect
mdl
promastigot
l
amazonensi
assess
method
similar
describ
previous
briefli
promastigot
count
use
neubauer
chamber
resuspend
fresh
medium
final
concentr
viabl
promastigotesml
viabil
assess
mobil
lack
stain
challeng
trypan
blue
inhibitor
compound
ad
cultur
final
concentr
start
mm
solut
dmso
serial
dilut
cultur
medium
dilut
dmso
correspond
use
prepar
drug
solut
assess
parallel
h
incub
c
number
viabl
motil
promastigot
quantifi
daili
count
flagel
neubauer
chamber
altern
parasit
grown
h
absenc
presenc
calpain
inhibitor
wash
five
time
cold
phosphatebuff
salin
pb
mm
nacl
mm
phosphat
buffer
ph
prior
resuspens
drugfre
fresh
medium
allow
grow
anoth
h
evalu
leishmanicid
leishmanistat
effect
number
live
promastigot
evalu
well
cell
morpholog
optic
microscopi
interv
lethal
dose
ld
ie
drug
concentr
caus
reduct
survivalvi
comparison
ident
cultur
without
compound
evalu
h
valu
determin
nonlinear
regress
analysi
plot
number
viabl
promastigot
versu
log
drug
concentr
use
origin
pro
comput
softwar
immunoblot
analysi
perform
total
cellular
extract
parasit
g
protein
obtain
previous
describ
primari
antibodi
use
rabbit
antisera
rais
drosophila
melanogast
calpain
antidmcalpain
kindli
provid
dr
yasufumi
emori
rais
whole
molecul
cystein
activ
site
histidin
activ
site
respect
human
brain
mcalpain
kindli
provid
dr
ralph
nixon
secondari
antibodi
use
horseradish
peroxidaseconjug
goat
antirabbit
immunoglobulin
g
igg
membran
develop
chemiluminesc
follow
exposur
radiograph
film
promastigot
cell
use
experi
fix
c
paraformaldehyd
pb
ph
min
follow
extens
wash
buffer
fix
cell
maintain
morpholog
integr
verifi
optic
microscopi
step
cell
incub
h
room
temperatur
dilut
rabbit
antidmcalpain
polyclon
antibodi
incub
addit
h
dilut
fluorescein
isothiocyan
fitc
label
goat
antirabbit
igg
cell
wash
three
time
pb
observ
zeiss
epifluoresc
microscop
axioplan
zeiss
oberkochen
germani
imag
digit
record
use
cool
ccdcamera
color
view
xs
analysi
gmbh
de
analys
analysi
system
softwar
altern
parasiteassoci
fluoresc
excit
nm
quantifi
fluorescenceactiv
cell
sorter
facscalibur
bd
bioscienc
san
ca
equip
mw
argon
laser
emit
nm
nontreat
cell
treat
secondari
antibodi
alon
run
parallel
control
experiment
popul
map
use
twoparamet
histogram
forwardangl
light
scatter
versu
side
scatter
map
popul
n
analys
log
green
fluoresc
use
singleparamet
histogram
experi
perform
triplic
three
independ
experiment
set
data
analys
statist
mean
student
ttest
use
epi
info
databas
statist
program
public
health
comput
softwar
pvalu
consid
statist
signific
mdl
potent
cellperm
inhibitor
calpain
ii
ad
replic
l
amazonensi
promastigot
form
differ
concentr
cell
growth
monitor
day
vitro
result
show
mdl
arrest
growth
l
amazonensi
dosedepend
manner
fig
calpain
inhibitor
induc
power
reduct
cellular
growth
rate
ca
h
respect
lowest
concentr
drug
present
signific
inhibitori
effect
h
growth
fig
convers
dmso
significantli
affect
parasit
growth
behaviour
ld
h
antileishmani
activ
irrevers
sinc
protozoa
pretreat
h
calpain
inhibitor
resum
growth
subcultur
fresh
medium
data
shown
corrobor
result
opti
fig
dmsotreat
cell
fig
addit
treatment
lower
concentr
calpain
inhibitor
initi
promot
increas
cell
volum
fig
lysi
parasit
cell
fig
base
effect
mdl
growth
rate
morpholog
l
amazonensi
aim
detect
calpain
homologu
protozoan
immunoblot
assay
use
differ
anticalpain
antibodi
fig
antidmcalpain
strongli
recognis
polypeptid
band
migrat
approxim
kda
fig
lane
common
epitop
found
mammalian
calpain
l
amazonensi
polypeptid
fig
lane
bd
lysat
mous
liver
recognis
antidmcalpain
antibodi
data
shown
calpainlik
molecul
detect
cell
surfac
l
amazonensi
demonstr
flow
cytometri
fluoresc
microscopi
analys
use
antidmcalpain
antibodi
fig
immunofluoresc
imag
show
label
throughout
cell
surfac
includ
flagellum
result
suggest
trypanosomatid
possess
molecul
share
antigen
invertebr
calpainrel
enzym
trypanosomatid
calpainrel
protein
alreadi
report
trypanosoma
brucei
crithidia
deanei
former
protein
shown
fig
fluoresc
microscopi
show
label
leishmania
amazonensi
antidmcalpain
antibodi
experiment
system
analys
differenti
interferenti
contrast
imag
c
immunofluoresc
b
bar
repres
express
procycl
bloodstream
trypomastigot
furthermor
protein
probabl
possess
stabl
interact
cell
membran
suggest
function
cellular
remodel
c
deanei
calpainrel
molecul
shown
proteolyt
activ
releas
cell
howev
function
determin
context
inhibit
leishmani
growth
produc
mdl
may
due
effect
calpainlik
molecul
result
add
new
vitro
insight
exploit
calpain
inhibitor
treat
parasit
infect
add
famili
proteas
list
potenti
target
develop
potent
specif
inhibitor
